News from pharmaceutical companies and other related healthcare organizations
MAR002 is an early, promising development: a new take on a proven strategy, with the potential for stronger IGF-1 control and dramatically less frequent dosing. At the same time, it’s important to keep expectations grounded. The drug is still investigational. It is not approved, not yet available outside clinical trials, and a larger patient study is needed to confirm what the early data suggest.
In this episode, Dr. Mario Maldonado from Recordati Rare Diseases discusses recent advances in endocrinology, focusing on hypercortisolism, diagnostic challenges, and innovative treatments. He shares insights from clinical studies and the future of AI in disease management.
For patients who’ve long faced one of the most treatment resistant forms of obesity, a new era may finally be here. For years, clinicians treating patients with acquired hypothalamic obesity (HO) have had little more
In today’s podcast, Crinetics co-founders Dr. Scott Struthers and Dr. Steve Betz share their views and experiences in drug discovery and development, revealing what it really takes to bring a new medication from concept to patients.
In the latest episode of the Pituitary World News podcast, Jorge D. Faccinetti sits down with Dr. Markus Johnsson, Senior VP of R&D at Camurus, to explore the fascinating world of FluidCrystal® technology. This innovative approach promises to revolutionize the way we think about drug delivery, providing long-lasting solutions for chronic diseases particularly for people with acromegaly.
We caught up with a group of top executives at Recordati at ENDO 2025 and asked them about their plans, challenges and opportunities and, importantly, their outlook for new therapies in acromegaly and Cushing’s.
Through our conversations with leading pituitary experts, physicians, nurses, industry executives, researchers, patient advocates, and other key stakeholders, we gain unique insights from the fascinating world of pituitary disease research and treatment.
Corcept Therapeutics recently announced the initiation of a clinical trial – called Momentum – to examining the prevalence of endogenous hypercortisolism (Cushing’s syndrome) in patients with resistant hypertension. The trial will enroll 1,000 patients across 45
A new TV ad links cortisol imbalance to Type 2 diabetes—raising awareness of overlooked endocrine factors.
We often scan the pituitary universe and report on the latest drug developments, new potential therapies, and engaging clinical cases and resources. We hope this knowledge helps people gain more insight into these complicated diseases and the fascinating medical/scientific discovery, research, and diagnosis world.
